Nie Zhenyu, Liu Bolong, Liu Jinhui, Zu Xiongbing, Wang Juanhua, Chen Jinbo, Fan Benyi, Deng Dingshan
Department of Urology, Xiangya Hospital, Central South University, Changsha, China.
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Biomark Res. 2024 Sep 27;12(1):112. doi: 10.1186/s40364-024-00657-y.
Resistance to immunotherapy in bladder cancer has greatly limited its clinical application. Through single-cell sequencing, we determined that ACSM6, an oncogene that is highly expressed in bladder cancer, promotes the abilities of proliferation, cloning, migration, and invasion. The key point is that ACSM6 can also lead to a non-inflammatory immune microenvironment by inhibiting the chemotaxis and tumor killing ability of CD8 T cells. Survival analysis revealed that high ACSM6 expression was associated with shorter overall survival in the immunotherapy cohort. In summary, ACSM6 is expected to become a novel biomarker for predict bladder cancer progression.
膀胱癌对免疫疗法的耐药性极大地限制了其临床应用。通过单细胞测序，我们确定ACSM6（一种在膀胱癌中高表达的癌基因）可促进细胞增殖、克隆、迁移和侵袭能力。关键在于，ACSM6还可通过抑制CD8 T细胞的趋化性和肿瘤杀伤能力导致非炎症性免疫微环境。生存分析显示，在免疫治疗队列中，ACSM6高表达与总生存期较短相关。总之，ACSM6有望成为预测膀胱癌进展的新型生物标志物。
